This study is testing a drug called ulixertinib for adults with recurrent gliomas (a type of brain tumor) that have specific genetic changes (MAPK-activated). The study wants to see if ulixertinib can get into the brain and tumor tissue. Some participants will take ulixertinib for two weeks before surgery to remove their tumor. Others, including those aged 12 and above, will take ulixertinib continuously in 28-day cycles without immediate surgery. Researchers are looking at how safe ulixertinib is, if it shrinks tumors, and how long people live or stay free from disease progression. To join, your tumor needs to show specific biomarkers like BRAF or FGFR.

Study design

This interventional study plans to enroll 40 participants. It is not specified if it is a single-arm or randomized study, nor is its phase specified.

What's involved

If you are in the surgical group, you will take ulixertinib twice a day for two weeks, then have tumor removal surgery. If you are in the non-surgical group, you will take ulixertinib twice a day continuously in 28-day cycles.

Compensation

Not stated in the trial record.

Follow-up

Adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.